Effect of nicorandil administration on cardiac burden and cardio-ankle vascular index after coronary intervention

Sato, Shuji; Takahashi, Mitsuru; Mikamo, Hiroshi; Kawazoe, Masayo; Iizuka, Takuo; Shimizu, Kazuhiro; Noro, Mahito; Shirai, Kohji

doi:10.1007/s00380-020-01650-9

Cited by 9 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Так, отказ от курения, физические тренировки, снижение веса приводят к снижению CAVI. Подобным действием обладают антидиабетические, липидснижающие, антигипертензивные (ингибиторы ренин-ангиотензин-альдостероновой системы, блокаторы минералокортикоидных рецепторов, прямые ингибиторы ренина) средства, нитроглицерин [9] и никорандил [42]. Не влияют на CAVI антагонисты кальция [9], а на фоне химиотерапии данный показатель повышается [43].…”

Section: влияние медикаментозной терапии и модификации поведения на Caviunclassified

Assessment of Arterial Stiffness Using the Cardio-Ankle Vascular Index – What We Know and What We Strive for

Sumin

Щеглова

2021

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Currently, the importance of assessing arterial stiffness as an integral indicator of cardiovascular risk, an indicator of arteriosclerosis, and a predictor of cardiovascular events has been demonstrated. The traditional indicator of arterial stiffness-pulse wave velocity-depends on the level of blood pressure, which makes it difficult to use it for dynamic assessment. The proposed new arterial stiffness index-the cardio-ankle vascular index (CAVI), does not depend on the level of blood pressure and is more convenient in practical use. CAVI has been widely used in clinical medicine for the past 15 years as an index for assessing cardiovascular diseases and risk factors, which has allowed for the expansion and deepening of research on this topic. This review focuses primarily on recent publications and new opportunities for evaluating vascular function using CAVI. The review provides information on solving methodological problems in evaluating CAVI, highlights the relationship between CAVI and future cardiovascular events, and provides cross-sectional data on the Association of CAVI with the presence of cardiovascular diseases and their risk factors. The results of studies on the effect of drug therapy and measures to control risk factors for cardiovascular diseases on CAVI are presented. While it remains unclear how much changes in CAVI over time can affect the forecast, research is currently being conducted in this direction. The use of CAVI also opens up new perspectives in the assessment of cardiovascular interactions, the study of vascular function in vasculitis and vascular injuries, as well as in geriatric medicine (concepts of premature vascular aging and excess vascular aging).

show abstract

Section: влияние медикаментозной терапии и модификации поведения на Caviunclassified

Assessment of Arterial Stiffness Using the Cardio-Ankle Vascular Index – What We Know and What We Strive for

Sumin

Щеглова

2021

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

show abstract

“…However, chances are not sure, except that nicorandil lacks specific liability in significant adverse cerebrovascular and cardiovascular occasions (MACCE). (18)Finally, the 2016 study by Ye et al suggested that nicorandil could prevent myocardial injury, lower the adverse reaction rate, and serve as an effective treatment for the Chinese population. Still, there is no clear indication for the non-Chinese population.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Nicorandil for Periprocedural Myocardial Injury in Patients Undergoing Pci

SHAH,

KHAN,

KHAN

2024

Biol Clin Sci Res J

View full text Add to dashboard Cite

Coronary artery disease (CAD) remains a leading cause of morbidity and mortality globally, with percutaneous coronary intervention (PCI) being a typical therapeutic approach. Objectives: In this comparative study, we aimed to investigate the efficacy and safety of nicorandil for periprocedural myocardial injury in patients undergoing PCI. Methods: This comparative study was conducted at Ayub Teaching Hospital from September 2023 to December 2023. Data from 90 patients was recruited for the research using inclusion and exclusion screening standards. Our study was performed on 90 patients treated with percutaneous coronary intervention (PCI). Patients from Group 1 were different from those in Group 2. Group A: the critical study parameters will switch between those patients who received nicorandil and Group B: non-nicorandil patients. Baseline demographic data, past medical history, and relevant laboratory values and clinical characteristics were documented for all patients. In addition, an intraoperative laboratory investigation was conducted, including cardiac biomarkers. Results: Research data were drawn from 90 patients whose gender wasn't a factor based on the research protocol. In Group A, the mean age of the patients was 62 years. Players in group A played for 4 ± 8.5 years. In team B, the players had a slightly longer experience and played for 63. Humans on Earth could do the same, and it could significantly impact future generations: ± 7. 9 years. Of 58 men and 32 women in the control group, there were two persons and persons in the experimental group, respectively. Only one stent differed between the two groups; however, the number was similar. 8 ± 0. 6 mmol/l in the tricorandil group and 1. +9 ± 0 in Case 1. Patients in the Nicorandil group displayed the lowest level of heart problem-causing protein (troponin) at the peak (5. There is a statistically significant 1.8-fold (2 ng/mL versus seven ng/mL) decline in serum lysozyme levels in the group administered rhG-CSF. The treatment group exhibited a substantial increase in haemoglobin levels (t(12) = 3. 74, p-value <0.005) with a mean difference of 0. 5 ± 2 ng/mL. 001, 95% CI: 2. 1 to 3. 5). Conclusion: It is concluded that nicorandil shows positive results for the efficacy (the ability of a drug to bring the desired effect) and safety of the drug in reducing myocardial injury and in maintaining the function of myocardial during percutaneous coronary intervention in patients.

show abstract

“…Reportedly, CAVI reflects functional stiffness in addition to structural stiffness of the arterial tree ( Shirai et al, 2011b ; Takahashi et al, 2012 ; Chiba et al, 2015 ; Shimizu et al, 2016 ; Sato et al, 2020 ). The adrenaline receptor α blocker doxazosin, which dilates arterial smooth muscles cells, is reported to decrease BP and decrease CAVI ( Shirai et al, 2011b ).…”

Section: Discussionmentioning

confidence: 99%

Changes in blood pressure and arterial stiffness monitored using the cardio–ankle vascular index during hemodialysis

Sato

Shimizu²,

Takahashi³

et al. 2023

Front. Physiol.

Self Cite

View full text Add to dashboard Cite

During hemodialysis (HD), blood pressure (BP) changes are frequently observed. However, the mechanism of BP changes during HD has not been fully clarified. The cardio–ankle vascular index (CAVI) reflects the arterial stiffness of the arterial tree from the origin of the aorta to the ankle independent from BP during measurement. Additionally, CAVI reflects functional stiffness in addition to structural stiffness. We aimed to clarify the role of CAVI in regulating the BP system during HD. We included 10 patients undergoing 4-hour HD (total 57 HD sessions). Changes in the CAVI and various hemodynamic parameters were evaluated during each session. During HD, BP decreased and CAVI significantly increased (CAVI, median [interquartile range]; 9.1 [8.4–9.8] [0 min] to 9.6 [9.2–10.2] [240 min], p < 0.05). Changes in CAVI from 0 min to 240 min were significantly correlated with water removal rate (WRR) (r = −0.42, p = 0.002). Changes in CAVI at each measurement point were negatively correlated with ΔBP (Δsystolic BPeach MP, r = −0.23, p < 0.0001; Δdiastolic BPeach MP, r = −0.12, p = 0.029). Whereas one patient exhibited a simultaneous decrease in BP and CAVI during the initial 60 min of HD. Arterial stiffness monitored with CAVI generally increased during HD. CAVI elevation is associated with decreased WWR and BP. An increase in CAVI during HD may reflect the contraction of smooth muscle cells and play an important role in BP maintenance. Hence, measuring CAVI during HD may distinguish the cause of BP changes.

show abstract

Effect of nicorandil administration on cardiac burden and cardio-ankle vascular index after coronary intervention

Cited by 9 publications

References 27 publications

Assessment of Arterial Stiffness Using the Cardio-Ankle Vascular Index – What We Know and What We Strive for

Assessment of Arterial Stiffness Using the Cardio-Ankle Vascular Index – What We Know and What We Strive for

Efficacy and Safety of Nicorandil for Periprocedural Myocardial Injury in Patients Undergoing Pci

Changes in blood pressure and arterial stiffness monitored using the cardio–ankle vascular index during hemodialysis

Contact Info

Product

Resources

About